Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Free Cash Flow (2020 - 2025)

SAB Biotherapeutics' Free Cash Flow history spans 6 years, with the latest figure at -$16.8 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 74.98% year-over-year to -$16.8 million; the TTM value through Dec 2025 reached -$44.8 million, down 29.3%, while the annual FY2025 figure was -$45.7 million, 31.99% down from the prior year.
  • Free Cash Flow reached -$16.8 million in Q4 2025 per SABSW's latest filing, down from -$13.1 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $7.6 million in Q1 2021 to a low of -$16.8 million in Q4 2025.
  • Average Free Cash Flow over 5 years is -$7.0 million, with a median of -$7.5 million recorded in 2021.
  • Peak YoY movement for Free Cash Flow: tumbled 72069.97% in 2021, then skyrocketed 85.07% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at -$7.2 million in 2021, then surged by 76.9% to -$1.7 million in 2022, then plummeted by 707.91% to -$13.5 million in 2023, then increased by 29.06% to -$9.6 million in 2024, then plummeted by 74.98% to -$16.8 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Free Cash Flow are -$16.8 million (Q4 2025), -$13.1 million (Q3 2025), and -$7.2 million (Q2 2025).